A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

The nature, incidence, and duration of adverse events monitored throughout the study by physical exam

Time frame: Screening, Wk 25 & Wk 52/EOT

Electrocardiogram will be performed at screening and during follow up visits to assess the safety and tolerability of the compound in terms of clinically significant cardiovascular changes

Time frame: Screening, Wk 4, Wk 25, Wk 52/EOT

The Columbia Suicide Severity Rating scale will be used to assess any suicide related adverse events

Time frame: As needed

The nature, incidence, and duration of adverse events monitored throughout the study by vital signs evaluation at each visit, weight measurements and clinical laboratory monitoring periodically

Time frame: Screening, Baseline, Wk 4, Wk 12, Wk 25, Wk 38, & Wk 52/EOT

All discontinuations due to adverse events will be reviewed throughout the trial to assess the safety and tolerability of the compound

Time frame: Weekly